-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the improvement of the strength of domestic innovative drug companies and their continuous recognition, License-out has gradually become a trend, and the international cooperation of medicine is becoming the new norm.
Among them, in the field of ADC drugs, the domestic ADC drug research and development track has become more and more crowd.
At present, more than 50 local companies have deployed ADC dru.
In this context, a group of powerful pharmaceutical companies' ADC drugs are accelerating their overseas launch through license out! CSPC Affiliates and Elevation Join HandsOn July 28, CSPC announced that CSPC Jushi Bio and Elevation, a subsidiary of CSPC, will join hands with Elevation, which will receive CSPC Jushi Bio’s innovative anti-Claudin12 antibody drug conjugate Development and commercialization rights of SYSA1801 outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwa.
Through the transaction, CSPC Jushi Bio will receive an upfront payment of $27 million and is entitled to receive potential development and regulatory milestone payments of up to $148 million and potential sales milestone payments of up to $02 billi.
CSPC Jushi is also entitled to a sales commission of up to a double-digit percentage based on the annual net sales of the product in the regi.
CSPC Jushi Bio will retain all rights to this product in Greater Chi.
It is reported that this is also another authorization of CSPC on the Claudin12 targ.
In August 2021, CSPC announced that its subsidiary NovaRock will grant the US innovative drug company Flame the exclusive right to develop, manufacture and commercialize the new anti-cancer drug NBL-015 outside of Greater Chi.
The total value of the deal could reach as much as $640 milli.
On July 26, Kelun Pharmaceuticals announced that its holding subsidiary Botai Bio and Merck had reached a cooperation and exclusive license agreement to develop an ADC drug for the treatment of solid tumors (project .
According to the announcement, Kelun Pharmaceuticals will exclusively license Merck to develop, manufacture and commercialize the ADC drug global.
The two parties will also collaborate on the early clinical development of the ADC dr.
According to the agreement, Merck will pay Kelun an upfront payment of US$35 million, various milestone payments of up to US$901 million and corresponding net sales commissions according to the content of the agreement and the stage of commercial developme.
It is reported that this is also the second time that Kelun Pharmaceuticals "sold medicine" to Merck within the ye.
In May of this year, Kelun Pharmaceutical announced a paid exclusive license to Merck to develop, manufacture and commercialize the ADC drug SKB-264 targeting TROP2 outside China (including mainland China, Hong Kong, Macau and Taiwa.
The deal includes an upfront payment of $47 million, milestone payments of up to $363 billion, and a royalty on net sales after the product goes on sa.
In addition to the above-mentioned pharmaceutical companies, since the beginning of this year, Lixin Pharmaceutical has licensed its self-developed innovative antibody-drug conjugate (ADC) LM-302 to Turning Point in the United States, and Hebo Pharmaceutical has licensed the company's HCAb-based immune cell interface (HBICE) platfo.
The resulting novel bispecific antibody HBM7022 was licensed to AstraZeneca for development and commercializati.
At present, the competition in the ADC drug market is fierce, and it is an option for pharmaceutical companies to go overseas through license o.
According to data from Southwest Securities, a total of 9 ADC drugs have been launched globally from 2019 to 2021, more than the sum of the previous two decad.
The scale of ADC drugs has also continued to gr.
In 2021, the global ADC drug sales have exceeded 5 billion US dollars, with an average compound growth rate of about 30% from 2014 to 202Entering 2022, the number of ADC drugs approved worldwide at the beginning of the year has reached 14, more than 150 are in the clinical research and development stage, and the drugs under development in the clinical phase III stage have also reached double digi.
According to the market forecast of Nature's sub-issue, by 2026, the global ADC drug market will reach 14 billion US dolla.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, in the field of ADC drugs, the domestic ADC drug research and development track has become more and more crowd.
At present, more than 50 local companies have deployed ADC dru.
In this context, a group of powerful pharmaceutical companies' ADC drugs are accelerating their overseas launch through license out! CSPC Affiliates and Elevation Join HandsOn July 28, CSPC announced that CSPC Jushi Bio and Elevation, a subsidiary of CSPC, will join hands with Elevation, which will receive CSPC Jushi Bio’s innovative anti-Claudin12 antibody drug conjugate Development and commercialization rights of SYSA1801 outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwa.
Through the transaction, CSPC Jushi Bio will receive an upfront payment of $27 million and is entitled to receive potential development and regulatory milestone payments of up to $148 million and potential sales milestone payments of up to $02 billi.
CSPC Jushi is also entitled to a sales commission of up to a double-digit percentage based on the annual net sales of the product in the regi.
CSPC Jushi Bio will retain all rights to this product in Greater Chi.
It is reported that this is also another authorization of CSPC on the Claudin12 targ.
In August 2021, CSPC announced that its subsidiary NovaRock will grant the US innovative drug company Flame the exclusive right to develop, manufacture and commercialize the new anti-cancer drug NBL-015 outside of Greater Chi.
The total value of the deal could reach as much as $640 milli.
On July 26, Kelun Pharmaceuticals announced that its holding subsidiary Botai Bio and Merck had reached a cooperation and exclusive license agreement to develop an ADC drug for the treatment of solid tumors (project .
According to the announcement, Kelun Pharmaceuticals will exclusively license Merck to develop, manufacture and commercialize the ADC drug global.
The two parties will also collaborate on the early clinical development of the ADC dr.
According to the agreement, Merck will pay Kelun an upfront payment of US$35 million, various milestone payments of up to US$901 million and corresponding net sales commissions according to the content of the agreement and the stage of commercial developme.
It is reported that this is also the second time that Kelun Pharmaceuticals "sold medicine" to Merck within the ye.
In May of this year, Kelun Pharmaceutical announced a paid exclusive license to Merck to develop, manufacture and commercialize the ADC drug SKB-264 targeting TROP2 outside China (including mainland China, Hong Kong, Macau and Taiwa.
The deal includes an upfront payment of $47 million, milestone payments of up to $363 billion, and a royalty on net sales after the product goes on sa.
In addition to the above-mentioned pharmaceutical companies, since the beginning of this year, Lixin Pharmaceutical has licensed its self-developed innovative antibody-drug conjugate (ADC) LM-302 to Turning Point in the United States, and Hebo Pharmaceutical has licensed the company's HCAb-based immune cell interface (HBICE) platfo.
The resulting novel bispecific antibody HBM7022 was licensed to AstraZeneca for development and commercializati.
At present, the competition in the ADC drug market is fierce, and it is an option for pharmaceutical companies to go overseas through license o.
According to data from Southwest Securities, a total of 9 ADC drugs have been launched globally from 2019 to 2021, more than the sum of the previous two decad.
The scale of ADC drugs has also continued to gr.
In 2021, the global ADC drug sales have exceeded 5 billion US dollars, with an average compound growth rate of about 30% from 2014 to 202Entering 2022, the number of ADC drugs approved worldwide at the beginning of the year has reached 14, more than 150 are in the clinical research and development stage, and the drugs under development in the clinical phase III stage have also reached double digi.
According to the market forecast of Nature's sub-issue, by 2026, the global ADC drug market will reach 14 billion US dolla.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
